<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01440621</url>
  </required_header>
  <id_info>
    <org_study_id>ModCRF</org_study_id>
    <nct_id>NCT01440621</nct_id>
  </id_info>
  <brief_title>Modafinil in Cancer Related Fatigue</brief_title>
  <acronym>ModCRF</acronym>
  <official_title>Randomized Controlled Study to Evaluate the Effects of Modafinil in Cancer Related Fatigue in Patients Undergoing Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Indira Gandhi Medical College</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Indira Gandhi Medical College</source>
  <brief_summary>
    <textblock>
      Cancer related fatigue (CRF) is a highly prevalent and highly significant entity among
      patients with cancer. 'Cancer related fatigue' is not a simple symptom, but is an entity in
      itself, in that it is different from routine fatigue. Cancer related fatigue is that fatigue
      which persists even after rest and has significant effects on quality of life.

      The incidence of Cancer Related Fatigue (CRF) increases during radiation therapy (RT), with
      almost every patient on radiotherapy complaining of at-least some magnitude of fatigue.

      Given that fatigue can affect treatment adherence by patients, it is important to initiate
      measures to either prevent or mitigate Cancer Related Fatigue.

      The investigators intend to use modafinil in cancer related fatigue, in view of the fact that
      it has safety and efficacy in other diseases such as narcolepsy, multiple sclerosis and
      fibromyalgia. In addition, there have been a few small trials which have hinted towards
      benefit with the use of modafinil in cancer related fatigue.

      The investigators have chosen a dose of 100mg/day in the morning, to be compared with
      placebo. The study arm and the placebo arm will be stratified with respect to age, sex,
      disease site, baseline performance status.

      Primary outcome would be fatigue, which will be assessed by the use of Brief Fatigue
      Inventory (BFI). Secondary outcomes include Quality of Life, improvements in performance
      status, changes in systolic and diastolic blood pressure, and changes in weight.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">February 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction in Cancer Related Fatigue</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Changes in Fatigue measured with the Brief Fatigue Inventory (BFI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in Quality of Life</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>The Spitzer Quality of Life Index (SQLI) to obtain Quality of Life (QOL) measurements.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Karnofsky Performance Status Scores</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Performance status scores measured with the Karnofsky Performance Status (KPS) scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of Modafinil on Systolic and Diastolic Blood Pressure</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in weight</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">217</enrollment>
  <condition>Cancer Related Fatigue</condition>
  <condition>Quality of Life</condition>
  <arm_group>
    <arm_group_label>Arm M</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Will be treated with Tab Modafinil (generic) 100mg Once a Day in the Morning starting from Day 1 of RT till the first follow-up.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm P</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Will be given placebo (Tab Pyridoxine 10mg) which physically resembles Tab Modafinil 100mg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Modafinil</intervention_name>
    <description>Tablet Modafinil 100mg (Generic) to be given in 100mg once a day dose, at 8AM daily in the morning, and to be given from Day 1 of Radiation Therapy till the first post treatment follow-up</description>
    <arm_group_label>Arm M</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyridoxine</intervention_name>
    <description>Tablet Pyridoxine 10mg once a day at 8AM daily, from Day one of RT till first post-treatment followup. Tab Pyridoxine 10mg has been chosen as placebo as it resembles Tab Modafinil 100mg in physical appearance, size and shape. Tab Pyridoxine is unlikely to affect Cancer Related Fatigue on its own as all patients on RT are already on multivitamin supplements as per our institutional guidelines.</description>
    <arm_group_label>Arm P</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with pathological confirmation of cancer

          -  Age 18 years to 70 years

          -  Performance status (Karnofsky scale) not less than 60

          -  Providing consent

        Exclusion Criteria:

          -  Psychiatric illness

          -  Hypertension

          -  Diabetes

          -  Thyroid disorders

          -  Epilepsy

          -  Tuberculosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Regional Cancer Centre</name>
      <address>
        <city>Shimla</city>
        <state>Himachal Pradesh</state>
        <zip>171001</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/20564068</url>
    <description>Link to a trial which utilized modafinil as an intervention for cancer related fatigue in 631 patients of breast cancer undergoing chemo</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/19416039</url>
    <description>A small study which showed that modafinil was well-tolerated and effective for fatigue in patients with cancer.</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/19318599</url>
    <description>A study which called for randomized trials with modafinil in cancer related fatigue</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/10091805</url>
    <description>Link to an article validating the Brief Fatigue Inventory (scale for fatigue assessment).</description>
  </link>
  <results_reference>
    <citation>Spathis A, Dhillan R, Booden D, Forbes K, Vrotsou K, Fife K. Modafinil for the treatment of fatigue in lung cancer: a pilot study. Palliat Med. 2009 Jun;23(4):325-31. doi: 10.1177/0269216309102614. Epub 2009 Mar 6.</citation>
    <PMID>19270033</PMID>
  </results_reference>
  <results_reference>
    <citation>Cooper MR, Bird HM, Steinberg M. Efficacy and safety of modafinil in the treatment of cancer-related fatigue. Ann Pharmacother. 2009 Apr;43(4):721-5. doi: 10.1345/aph.1L532. Epub 2009 Mar 24. Review.</citation>
    <PMID>19318599</PMID>
  </results_reference>
  <results_reference>
    <citation>Blackhall L, Petroni G, Shu J, Baum L, Farace E. A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. J Palliat Med. 2009 May;12(5):433-9. doi: 10.1089/jpm.2008.0230.</citation>
    <PMID>19416039</PMID>
  </results_reference>
  <results_reference>
    <citation>Wirz S, Nadstawek J, KÃ¼hn KU, Vater S, Junker U, Wartenberg HC. [Modafinil for the treatment of cancer-related fatigue : an intervention study]. Schmerz. 2010 Dec;24(6):587-95. doi: 10.1007/s00482-010-0987-y. German.</citation>
    <PMID>21046171</PMID>
  </results_reference>
  <results_reference>
    <citation>Jean-Pierre P, Morrow GR, Roscoe JA, Heckler C, Mohile S, Janelsins M, Peppone L, Hemstad A, Esparaz BT, Hopkins JO. A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer. 2010 Jul 15;116(14):3513-20. doi: 10.1002/cncr.25083.</citation>
    <PMID>20564068</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2011</study_first_submitted>
  <study_first_submitted_qc>September 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 26, 2011</study_first_posted>
  <last_update_submitted>March 21, 2012</last_update_submitted>
  <last_update_submitted_qc>March 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Indira Gandhi Medical College</investigator_affiliation>
    <investigator_full_name>Swaroop Revannasiddaiah</investigator_full_name>
    <investigator_title>Post-Graduate in Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>Cancer related fatigue</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Modafinil</keyword>
  <keyword>Radiation therapy</keyword>
  <keyword>Radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Pyridoxine</mesh_term>
    <mesh_term>Pyridoxal</mesh_term>
    <mesh_term>Vitamin B 6</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

